A Phase 1 Study of ADI-001 in Autoimmune Disease

Study Number

4342824

Phase

Age Group

Adult

Principal Investigator

Purpose

ADI-202300103 is a phase 1 multicenter, open label, dose finding and dose expansion, safety/efficacy study in patients with autoimmune disease. The study will consist of different periods including screening, lymphodepletion, treatment, and follow-up

Check your eligibility for this trial

Check now

Full Title

A Phase 1 Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta T Cells in Adults with Autoimmune Disease (ADI-202300103)

ClinicalTrials.Gov ID

NCT06375993

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.